Saturday 17 October 2026
Export ALVO’s income statement to Excel — free account
Alvotech
ALVO Healthcare Drug Manufacturers Specialty & Generic
Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,311.0%, EPS fell 99.5%, free cash flow fell 496.6% and total debt rose 16.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
5.00
0.31
−5.84%
Follow ALVO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 3 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 76.00 | — | — |
Altman Z-Score |
(0.98) | (0.65) | (3.64) | (3.13) | — | — | — |
P/S ratio |
7.60 | 43.41 | 49.04 | 0.00 | 0.00 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(3.91) | (4.98) | (11.06) | (9.24) | (8.97) | — | — |
Beneish M-Score |
(2.68) | 0.07 | — | (1.25) | — | — | — |
P/Operating CF |
114.60 | (16.45) | (12.39) | (38.66) | (4.80) | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Sales |
13.47 | 56.99 | 64.38 | 0.00 | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
(22.15) | (7.51) | (9.20) | (6.49) | (6.47) | — | — |
EV/FCF |
(9.40) | (6.65) | (7.48) | (5.23) | (6.47) | — | — |
Quick Ratio |
0.80 | 1.10 | 0.20 | 0.60 | 0.43 | 3.35 | — |
Current Ratio |
1.89 | 2.35 | 0.75 | 1.38 | 1.07 | 4.00 | — |
Net Debt/EBITDA |
9.71 | 10.08 | (2.87) | (2.14) | (1.76) | 4.27 | — |
Debt/Assets |
87.36% | 87.49% | 101.06% | 92.29% | 67.04% | 0.05% | 0.00% |
Debt/Equity |
(4.57) | (2.59) | (1.03) | (1.35) | (2.96) | 0.00 | — |
Asset Turnover |
0.43 | 0.45 | 0.10 | 0.12 | 0.09 | 0.00 | — |
Operating CF/Net income |
(1.80) | 1.02 | 0.57 | 0.61 | 2.25 | 0.03 | — |
Capex/Depreciation |
(2.54) | (1.82) | (1.91) | (2.38) | (2.23) | — | — |
Interest Coverage |
0.52 | 0.23 | (1.33) | (1.84) | (2.01) | — | — |
| (8.01%) | 34.47% | 73.72% | 146.73% | 123.27% | (4.16%) | — | |
| 2.06% | (21.36%) | (62.04%) | (72.01%) | (23.90%) | (7.37%) | — | |
ROIC |
5.80% | 7.20% | (1,343.43%) | (161.92%) | (59.40%) | 0.00% | — |
Return on Tangible Assets |
4.46% | (42.45%) | (323.27%) | (180.82%) | (117.33%) | (809.43%) | — |
Average Days of Receivables |
43.69 | 119.51 | 168.41 | 151.75 | 302.81 | — | — |
Research and Development Expense of Revenue |
31.42% | 34.98% | 230.58% | 217.54% | 519.43% | — | — |
Selling, General and Administrative Expense of Revenue |
15.51% | 13.42% | 83.73% | 224.91% | 228.80% | 0.00% | — |
Intangible Assets out of Total Assets |
0.06 | 0.03 | 0.03 | 0.05 | 0.06 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.26% | 1.56% | 19.72% | 12.43% | 0.00% | — | — |
Graham Net Nets |
(0.82) | (0.36) | (0.56) | (0.47) | (0.56) | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 14.18 | 5.03 | — | — |
Earnings Yield |
(9.36%) | (15.95%) | (22.10%) | (39.34%) | 1.32% | — | — |
Free Cash Flow Yield |
(18.87%) | (19.75%) | (17.54%) | (24.49%) | (20.87%) | — | — |
Revenue per Share |
2.02 | 1.83 | 0.40 | 0.42 | 0.33 | 0.00 | — |
Operating CF per Share |
(0.17) | (0.88) | (1.37) | (1.58) | (2.06) | (0.05) | — |
Capex per Share |
(0.33) | (0.21) | (0.20) | (0.25) | (0.37) | 0.00 | — |
Free Cash Flow per Share |
(0.50) | (1.10) | (1.58) | (1.83) | (2.43) | (0.05) | — |
Cash per Share |
0.59 | 0.19 | 0.05 | 0.34 | 0.16 | 0.21 | — |
Shareholders Equity per Share |
(0.98) | (1.54) | (4.10) | (2.85) | (1.23) | (4.80) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(0.98) | (1.54) | (4.10) | (2.85) | (1.23) | (4.80) | — |
Free Cash Flow |
(146.33) | (293.84) | (358.52) | (361.01) | (268.80) | (0.32) | — |
Working Capital |
269.94 | 261.62 | (66.11) | 63.44 | 7.98 | 1.15 | — |
Capital Expenditures |
(96.13) | (57.00) | (46.34) | (48.62) | (40.63) | — | — |
Net Current Asset Value |
(1,197.57) | (1,179.15) | (1,687.74) | (1,162.12) | (613.77) | (279.08) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.16 | 0.12 | 0.51 | 0.59 | 1.11 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
0.11 | 0.11 | 0.10 | 0.09 | 0.23 | — | — |
Cash ROIC |
(12.33%) | (41.55%) | (923.49%) | (135.42%) | (95.03%) | 1.14% | — |
Accounts Receivable Turnover |
5.09 | 4.84 | 2.38 | 2.55 | 0.00 | — | — |
Accounts Payable Turnover |
2.44 | 2.51 | 2.48 | 1.65 | 0.00 | 0.00 | — |
Inventory Turnover |
1.35 | 1.83 | 2.21 | 1.16 | — | — | — |
Average Days of Payables |
195.43 | 132.22 | 182.81 | 280.11 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
340.98 | 251.90 | 168.90 | 407.00 | 0.00 | — | — |
Average Receivables |
115.26 | 101.26 | 38.35 | 32.51 | — | — | — |
Average Payables |
96.63 | 73.84 | 64.88 | 38.89 | 14.30 | 0.12 | — |
Average Inventory |
173.97 | 101.16 | 72.95 | 55.26 | — | — | — |
Average Assets |
1,354.25 | 1,085.75 | 889.27 | 713.21 | 424.76 | 125.77 | — |
Average Common Equity |
(348.63) | (672.63) | (748.45) | (350.01) | (82.34) | 222.92 | — |
Columns are period end dates